{"id":"hl140-20-10","safety":{"commonSideEffects":[]},"_chembl":null,"_dailymed":null,"mechanism":{"_ai_source":"claude-haiku-4.5","explanation":"Without publicly available detailed information on HL140's specific molecular targets and mechanism of action, the exact pharmacological pathway cannot be definitively stated. The designation '20/10' indicates a fixed-dose combination of two components at those respective doses, currently in phase 3 clinical development.","oneSentence":"HL140 20/10 is a fixed-dose combination product from Hanlim Pharm that combines two active pharmaceutical ingredients in a 20/10 mg ratio.","_ai_confidence":"low"},"_scrapedAt":"2026-03-28T00:44:49.040Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[]},"trialDetails":[{"nctId":"NCT03571087","phase":"PHASE3","title":"Efficacy and Safety of Combination of Rosuvastatin and Ezetimibe in Patients With Primary Hypercholesterolemia","status":"COMPLETED","sponsor":"Hanlim Pharm. Co., Ltd.","startDate":"2014-09","conditions":"Primary Hypercholesterolemia","enrollment":374}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":0,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":[],"phase":"phase_3","status":"active","brandName":"HL140 20/10","genericName":"HL140 20/10","companyName":"Hanlim Pharm. Co., Ltd.","companyId":"hanlim-pharm-co-ltd","modality":"Small molecule","firstApprovalDate":"","aiSummary":"","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":0,"withResults":0},"verificationStatus":"partial","dataCompleteness":{"mechanism":true,"indications":false,"safety":false,"trials":true,"score":2}}